ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Eyebiotech Limited

Eyebiotech Limited is an active company incorporated on 9 July 2021 with the registered office located in London, City of London. Eyebiotech Limited was registered 4 years ago.
Status
Active
Active since incorporation
Company No
13503296
Private limited company
Age
4 years
Incorporated 9 July 2021
Size
Unreported
Confirmation
Submitted
Dated 8 July 2025 (4 months ago)
Next confirmation dated 8 July 2026
Due by 22 July 2026 (8 months remaining)
Last change occurred 3 months ago
Accounts
Submitted
For period 1 Jan31 Dec 2023 (12 months)
Accounts type is Group
Next accounts for period 31 December 2024
Due by 31 December 2025 (1 month remaining)
Address
120 Moorgate
London
EC2M 6UR
England
Address changed on 16 Jan 2025 (9 months ago)
Previous address was International Building 71 Kingsway Holborn London WC2B 6st United Kingdom
Telephone
Unreported
Email
Unreported
People
Officers
13
Shareholders
1
Controllers (PSC)
1
Director • Director • Chartered Accountant • British • Lives in UK • Born in Jun 1968
Director • Director • British • Lives in UK • Born in Nov 1974 • Managing Director Pharmaceuticals
Director • SVP, Chief Clinical Operations Officer • American • Lives in United States • Born in May 1962
Director • Self-Employed • American • Lives in United States • Born in Dec 1959
Director • American • Lives in United States • Born in Mar 1968
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
Merck Sharp & Dohme (UK) Limited
Benjamin Paul Lucas is a mutual person.
Active
MSD R&D Innovation Centre Limited
Benjamin Paul Lucas is a mutual person.
Active
Schering-Plough Holdings Limited
Benjamin Paul Lucas is a mutual person.
Active
Merck Sharp & Dohme Finance Europe Limited
Benjamin Paul Lucas is a mutual person.
Active
MSD Limited
Benjamin Paul Lucas is a mutual person.
Active
SV Health Investors UK Limited
Dame Catherine Elizabeth Bingham is a mutual person.
Active
Pulmocide Limited
Dame Catherine Elizabeth Bingham is a mutual person.
Active
Autifony Therapeutics Limited
Dame Catherine Elizabeth Bingham is a mutual person.
Active
Financials
Net Assets, Total Assets & Total Liabilities (2022–2023)
Period Ended
31 Dec 2023
For period 31 Dec31 Dec 2023
Traded for 12 months
Cash in Bank
£38.63M
Increased by £29.09M (+305%)
Turnover
Unreported
Same as previous period
Employees
20
Increased by 13 (+186%)
Total Assets
£49.26M
Increased by £31.84M (+183%)
Total Liabilities
-£6.56M
Increased by £725K (+12%)
Net Assets
£42.7M
Increased by £31.12M (+269%)
Debt Ratio (%)
13%
Decreased by 20.2% (-60%)
Latest Activity
Confirmation Submitted
3 Months Ago on 21 Jul 2025
Registered Address Changed
9 Months Ago on 16 Jan 2025
Group Accounts Submitted
1 Year 2 Months Ago on 19 Aug 2024
Confirmation Submitted
1 Year 3 Months Ago on 19 Jul 2024
Merck & Co., Inc. (PSC) Appointed
1 Year 4 Months Ago on 11 Jul 2024
David R Guyer Resigned
1 Year 4 Months Ago on 11 Jul 2024
Anthony Peter Adamis Resigned
1 Year 4 Months Ago on 11 Jul 2024
Andreas Wallnofer Resigned
1 Year 4 Months Ago on 11 Jul 2024
Evelyn Melinda Harrison Resigned
1 Year 4 Months Ago on 11 Jul 2024
Bernard Thomas Davitian Resigned
1 Year 4 Months Ago on 11 Jul 2024
Get Credit Report
Discover Eyebiotech Limited's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Confirmation statement made on 8 July 2025 with updates
Submitted on 21 Jul 2025
Resolutions
Submitted on 15 May 2025
Memorandum and Articles of Association
Submitted on 12 May 2025
Registered office address changed from International Building 71 Kingsway Holborn London WC2B 6st United Kingdom to 120 Moorgate London EC2M 6UR on 16 January 2025
Submitted on 16 Jan 2025
Group of companies' accounts made up to 31 December 2023
Submitted on 19 Aug 2024
Statement of capital following an allotment of shares on 11 July 2024
Submitted on 26 Jul 2024
Statement of capital following an allotment of shares on 11 July 2024
Submitted on 25 Jul 2024
Statement of capital following an allotment of shares on 11 July 2024
Submitted on 24 Jul 2024
Notification of Merck & Co., Inc. as a person with significant control on 11 July 2024
Submitted on 24 Jul 2024
Statement of capital following an allotment of shares on 11 July 2024
Submitted on 23 Jul 2024
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year